AVITA Medical (RCEL) Q2 2024 earnings summary

Executive summary

• Q2 2024 commercial revenue reached up to $19.5 million, reflecting year-over-year growth between 29% and 44%, driven by deeper market penetration, new account adoption, and product innovation for full-thickness skin defects and burns.

• FDA approved RECELL GO in May 2024, with immediate launch and first case completed; RECELL GO mini PMA supplement submitted in June.

• Expanded product portfolio with PermeaDerm and a new collagen-based dermal matrix through partnership with Regenity Biosciences.

• Strategic transformation underway to offer a continuum of wound care, integrating new dermal matrices and dressings.

• Progressed international expansion with new distribution agreements in multiple European countries.

Financial highlights

• Q2 2024 commercial revenue ranged from $15.1 million to $19.5 million, up 29–44% year-over-year.

• Gross profit margin improved to 86.2% from 81.2% in Q2 2023.

• Operating expenses rose to $28.7 million, mainly due to sales and marketing expansion.

• Net loss was $15.4 million ($0.60 per share), compared to $10.4 million ($0.41 per share) in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $54.1 million as of June 30, 2024.

Outlook and guidance

• Q3 2024 commercial revenue guidance set at $19–$20 million, representing 40–48% year-over-year growth.

• Full-year 2024 revenue guidance revised to $68–$70 million, reflecting over 37% annual growth.

• Targeting cash flow break-even and GAAP profitability by Q3 2025, driven by top-line growth.

• Anticipate FDA approval of RECELL GO mini by December 27, 2024, and 510(k) clearance for Regenity dermal matrix in Q4 2024.

• Management expects sufficient cash reserves to fund operations for the next 12 months.